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1430 The Journal of Thoracic and CardObjectives: Cell transplantation prevents chamber
dilatation, but the underlying molecular mechanisms
remain undefined. Structural cardiac remodeling in-
volves matrix degradation from an imbalance of ma-
trix metalloproteinases (MMP) relative to endogenous tissue inhibitors of metallopro-
teinases (TIMP). We aimed to determine the capacity of cell transplantation to alter
extracellular matrix in the failing heart and, in so doing, identify novel paracrine
molecular mediators underlying the beneficial effects of cell transplantation on chamber
dilatation.
Methods: Smooth muscle cells were transplanted to the dilating left ventricle of cardio-
myopathic hamsters (CTX, n  15) compared with age-matched media-injected cardio-
myopathic (CON, n  15) and normal hamsters (n  7). After 5 weeks, left ventricular
volume was measured by computerized planimetry. Fibrillar collagen was examined by
confocal microscopy. Matrix homeostasis was quantified by measuring MMP/TIMP ex-
pression/activity relative to myocardial collagen synthesis (14C-proline uptake).
Results: Left ventricular dilatation was attenuated in CTX hearts (P  .02). CTX
restored perimysial collagen fiber content and architecture to normal levels. TIMP-2 and
TIMP-3 expression were enhanced in CTX (TIMP-2, 195%  42% of CON, P  .02;
TIMP-3, 118%  3% of CON, P  .002), and correspondingly, gelatinase MMP-2
activity was reduced (P  .05). The TIMP:MMP ratio was increased in CTX hearts
(TIMP-2 to MMP-2, 410%  134% of CON, P  .04, and TIMP-3 to MMP-9, 205%
 47% of CON, P  .03), reflecting a reduced capacity for matrix degradation.
Collagen synthesis was equivalent (CTX vs CON), suggesting that restored matrix
architecture was a function of attenuated matrix degradation.
Conclusions: These data provide the first evidence that cell transplantation limits
ventricular dilatation in the failing heart through a paracrine-mediated mechanism that
preserves extracellular matrix homeostasis.
The evolving clinical reality that cell transplantation can limit cardiac dilata-tion and the progression of heart failure is overshadowed by an absence ofmolecular and cellular mechanisms underlying the beneficial effects of cell
Dr Fedakengraftment. An improved understanding of the host t
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its evolving therapeutic use.
Muscle cell transplantation in failing hearts has con-
sistent and predictable benefits on limiting left ventricu-
lar dilatation and dysfunction, irrespective of the donor
tissue source (cardiac, skeletal, or smooth muscle).1-3
Despite a relatively small mass of transplanted cells and
substantial cell losses after injection into the heart, mal-
adaptive cardiac remodeling is somehow profoundly at-
tenuated. This intriguing phenomenon indicates that the
continued presence of the cells themselves may not be
necessary to improve cardiac function and contradicts the
belief that the cells themselves contribute to useful con-
tractile work. Accordingly, it has been proposed that the
beneficial effects of cell transplantation may be a conse-
quence of newly expressed bioactive mediators promoted
by the process of cell engraftment. However, the bioac-
tive peptides that mediate this proposed paracrine effect
of transplanted cells remain elusive.
In the failing heart, dysregulation of extracellular matrix
(ECM) plays a central role in maladaptive cardiac remod-
eling and the transition to overt congestive heart failure,
largely by an enhanced activity of matrix metalloproteinases
(MMPs), a family of enzymes that degrade key matrix
components.4-7 Activation of matrix proteases in the injured
heart results in matrix scaffold degradation and resultant
chamber thinning, dilatation, and a poorly coordinated con-
traction. Tissue inhibitors of metalloproteinases (TIMPs)
are complex endogenous biomolecules capable of inactivat-
ing the enzymes that degrade matrix components.8 How-
ever, TIMPs are relatively deficient in the failing heart.9,10
We previously determined that a reduction in TIMP expres-
sion paralleled matrix disruption and left ventricle (LV)
dilatation in hamster cardiomyopathy.9 We later demon-
strated in mutant mice that reduced TIMP expression accel-
erated matrix degradation and induced a progressive dilated
cardiomyopathy similar to human heart failure.11 In this
study, we hypothesize that muscle cell transplantation en-
hances myocardial TIMP expression and reorganizes dam-
aged matrix elements resulting in attenuated chamber dila-
Abbreviations and Acronyms
ECM  extracellular matrix
LV  left ventricle
MMP matrix metalloproteinase
SEM  standard error of mean
SMC  smooth muscle cell
TIMP  tissue inhibitor of metalloproteinase
VSMC vascular smooth muscle celltation.
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Experimental Animals
The Animal Care Committee of the Toronto General Research
Institute approved all procedures performed on animals. All
experiments were performed according to the “Guide to the
Care and Use of Experimental Animals of the Canadian Council
on Animal Care.” The Syrian hamster with a genetic dilated
cardiomyopathy (BIO 53.58 hamster, Bio Breeders Inc, Fitch-
burg, Mass) was used. Age-matched normal F1- hamsters
served as nonfailing controls (Charles River Canada Inc, Que-
bec, Canada). Donor muscle cells were freshly isolated from
4-week-old hamsters. Cardiomyopathic hamsters at 20 weeks
of age (predilatation phase) were used as cell transplant
recipients.
Cell Processing and Transplantation
Vascular smooth muscle cells (VSMCs) were isolated as pre-
viously described.12 A volume of 0.04 mL of cell suspension or
culture medium alone was then transplanted into each heart to
deliver 4 million cells. Recipient hamsters were anesthetized
and transplanted using a single injection on the surface of the
anterior LV free wall. The surgical method was performed as
previously described.12 All hamsters were euthanized by anes-
thetic overdose at 5 weeks from the time of cell transplantation.
In the first group of experiments, the anterior free wall of the
LV was snap-frozen in liquid nitrogen and stored at 80°C for
enzyme analysis. In a separate group of hamsters, hearts were
arrested in diastole and pressure-fixed at 30 mm Hg in formalin
and examined for ventricular geometry by planimetry and
stained for collagen content and architecture as described
next.
Immunoblotting
The relative abundance of MMPs and TIMPs was examined in LV
myocardial extracts using standard immunoblotting procedures as
previously described.9
Matrix Metalloproteinase Gelatin Zymography
Gelatinase activity (MMP-2 and MMP-9) was semiquantified by
gelatin zymography as previously described.13
Collagen Synthesis
Collagen synthesis in LV myocardium was then determined using
the method of Strauss and colleagues as previously described.9 The
rate of collagen synthesis was determined by the rate of
14C-proline incorporation into myocardial collagen.
Confocal Microscopy
Formalin-treated heart sections were imaged using a laser scanning
confocal system (BioRad MRC 1024, Bio-Rad Laboratories, Her-
cules, Calif) after treatment with 0.2% phosphomolybdic acid (pH
1.8-2.2) and 0.1% picrosirius red to selectively stain collagens.
Collagen content and fiber architecture were assessed as previ-
ously described.9
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The left ventricular volume was measured using image analysis of
pressure-fixed heart specimens as previously described.12
Statistical Analysis
Results are presented as mean  standard error of mean (SEM).
Comparison between groups was performed by 1-way analysis of
variance. If the F ratio was significant, pairwise tests of individual
group means were compared using the Student-Newman-Keuls
test. All statistical procedures were performed using the SAS
1432 The Journal of Thoracic and Cardiovascular Surgery ● Novsoftware system (SAS Institute, Cary, NC). The critical -level for
these analyses was set at P  .05.
Results
Smooth Muscle Cell Phenotype and Engraftment
Engraftment of VSMCs in the LV of dilated cardiomyo-
pathic hamsters was observed only in cell-transplanted
hearts and was made possible using immunostaining and
Figure 1. Cell transplantation and smooth
muscle cell (SMC) engraftment. Top, Vascular
smooth muscle cells (VSMCs) in culture ex-
pressed SMC-specific actin (red) confirming
an SMC phenotype and expression of con-
tractile proteins. Middle, Engraftment of
VSMCs in the left ventricle (LV) of dilated
cardiomyopathic hamsters was observed
only in cell-transplanted hearts and was
made possible with immunostaining (desmin
in green, left; SMC-specific actin in red, right)
and confocal microscopy. Bottom, In the
merged image, engrafted VSMCs were iden-
tified within viable myocardial regions as
elongated rod-shaped cells (dotted arrows)
distinct from adjacent blood vessel walls
(solid arrows) and cardiomyocytes (400
magnification).confocal microscopy (Figure 1). Engrafted VSMCs were
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rod-shaped cells distinct from adjacent blood vessel walls
and cardiomyocytes. The engrafted cells appeared to
orient and align in parallel to adjacent cardiomyocytes.
The positive immunostaining of the engrafted cells with
smooth muscle cell (SMC)-specific actin suggests that
the engrafted cells were in a contractile phenotype sim-
ilar to those in the quiescent medial layer of the adjacent
blood vessel walls.
Differential Tissue Metalloproteinase Expression
Engraftment of VSMCs by cell transplantation in the LV
altered the expression and content of TIMPs in the failing
heart (Figure 2). Specifically, TIMP-1 expression was
reduced, but not significantly, and expression of both
TIMP-2 and TIMP-3 was significantly increased. Nota-
bly, TIMP-3 expression was restored toward normal
levels, whereas TIMP-2 expression was increased ap-
proximately 2-fold. These data indicate that cell trans-
plantation with VSMCs can enhance the expression of
Figure 2. Differential TIMP expression and cell transplantation.
Engraftment of VSMCs in the LV of dilated cardiomyopathic hamsters
altered the expression of TIMP species. TIMP-2 and TIMP-3 expres-
sion was significantly enhanced and the pathologic increases in
TIMP-1 were limited, although only a trend was observed. TIMP-4, a
TIMP species not usually expressed by SMCs, was unchanged after
cell transplantation. TIMP, Tissue inhibitor of metalloproteinase;
DCM, media-injected dilated cardiomyopathic hamsters (n  8);
DCMCTx, cell-transplanted dilated cardiomyopathic hamsters (n
 11). Bars represent mean  standard error of mean (SEM).TIMP-2 and TIMP-3 in hamster cardiomyopathy.
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Cell transplantation did not significantly alter the expres-
sion of MMP-2 and MMP-9 in hamster cardiomyopathy
(Figure 3). However, TIMP to MMP stoichiometry was
altered. Specifically, the ratio of TIMP-3 to MMP-9
expression was increased in cell-transplanted hearts (P 
.03), and the ratio of TIMP-2 to MMP-2 was increased
more than 3-fold in cell-transplanted hearts (P  .04).
Matrix Metalloproteinase Gelatinase Activity
MMP-2 activity was significantly reduced in cell-trans-
planted cardiomyopathic myocardium compared with
media-injected cardiomyopathic controls (Figure 4).
Similarly, MMP-9 activity was reduced in cell-trans-
planted hearts, but the difference was not statistically
significant (P  .1).
Collagen Synthesis
Collagen synthesis was elevated in cardiomyopathic myo-
cardium compared with normal nonfailing controls (P 
.001, Figure 4). Collagen synthesis was increased to a
similar extent in both cell-transplanted and control hearts
Figure 3. MMP expression and TIMP:MMP expression ratio. Cell
transplantation did not significantly influence the expression of
MMP-2 and MMP-9 after cell transplantation at 5 weeks. How-
ever, the ratio of TIMP-2 to MMP-2 and TIMP-3 to MMP-9 ex-
pression was increased in cell-transplanted hearts indicating a
reduced capacity for matrix degradation. Bars represent mean 
SEM. TIMP, Tissue inhibitor of metalloproteinase; MMP, matrix
metalloproteinase; DCM, media-injected dilated cardiomyopathic
hamsters; DCMCTx, cell-transplanted dilated cardiomyopathic
hamsters.(P  .76, Figure 4).
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We previously documented that hamster cardiomyopathy
is associated with reduced perimysial collagen content
with fiber fragmentation and thinning consistent with
accelerated matrix degradation.9 In viable regions of LV
myocardium, confocal microscopy and a blinded com-
puterized image analysis determined that the reduced
regional collagen content characteristic of hamster car-
diomyopathy was prevented by cell transplantation at 5
weeks compared with media-injected controls (Figure 5).
In addition, the length and diameter of perimysial colla-
gen fibers in viable regions of myocardium were assessed
in cell-transplanted hearts and compared with age-
matched media-injected controls. Notably, cell transplan-
tation limited the characteristic reduction in collagen
fiber length and diameter observed in hamster cardiomy-
Figure 4. Collagen degradation and synthesis. Top, Matrix-degrad-
ing capacity was inferred by gelatinase MMP activity as assessed
by gelatin zymography. MMP-2 activity was attenuated in the cell-
transplanted hearts (P  .04, n  7) and MMP-9 activity was
reduced, but the difference was not statistically significant (P .1).
Bottom, Collagen synthesis was assessed by radiolabeled proline
uptake in ex vivo myocardial tissue segments. Collagen synthesis
was elevated in cardiomyopathic hamster myocardium compared
with normal nonfailing hamster myocardium but was not signifi-
cantly different between cell-transplanted and media-injected car-
diomyopathic groups. Bars represent mean  SEM. *P< .05. TIMP,
Tissue inhibitor of metalloproteinase; DCM, media-injected dilated
cardiomyopathic hamsters (n  8); DCMCTx, cell-transplanted
dilated cardiomyopathic hamsters (n  11); NF, nonfailing normal
hamsters (n  6).opathy (Figure 5). The appearance of the perimysial
1434 The Journal of Thoracic and Cardiovascular Surgery ● Novcollagen fibers in the cell-transplanted hearts was similar
to that in nonfailing normal hamsters (Figure 6).
Left Ventricular Chamber Volume
LV dilatation is a hallmark of maladaptive structural cardiac
remodeling and a strong predictor of late mortality in pa-
tients with ventricular dysfunction.14,15 LV geometry was
assessed by computerized planimetry of heart sections. The
VSMC-transplanted chamber volumes (76  14 L) were
smaller than media-injected controls (97 16 L, P .02)
and approached those of age-matched normal hearts (60 
6 L). These data indicate that VSMC cell transplantation
limited ventricular dilatation, data that are consistent with
Figure 5. Fibrillar collagen abundance and architecture. Cell
transplantation using VSMCs prevented the characteristic loss of
collagen content and fiber architecture in viable regions of LV
myocardium as assessed by confocal microscopy and a blinded
computerized image analysis. Bars represent mean  SEM. *P <
.05. **P < .05 for DCM versus DCMCTx. DCM, Media-injected
dilated cardiomyopathic hamsters (n  4); DCMCTx, cell-trans-
planted dilated cardiomyopathic hamsters (n  4); NF, nonfailing
normal hamsters (n  4).our prior observations.2,12,16
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The cellular and molecular mechanisms that mediate the
functional benefits after cell transplantation observed in the
failing heart are not clear. An active process whereby the
engrafted cells replace lost contractile elements and contract
synchronously with the host myocardium may occur. Leo-
bon and colleagues17 recently demonstrated that skeletal
myoblasts are capable of contraction after implantation into
ischemic heart tissue, but the implanted cells were not
coupled to native heart cells. Although transplanted cells
may indeed contract in host myocardium under specific
conditions, it remains to be determined whether the active
contraction of implanted cells is responsible for the im-
provements of systolic function observed after cell trans-
plantation. The number of cells that ultimately survive and
engraft in the host myocardium after direct injection is
limited and extremely small relative to total cardiac mass.18
Given the consistent observation of reduced cell survival
after cell transplantation, active contraction of such a lim-
ited number of engrafted cells as the primary mechanism of
improved contractile function is unlikely. Similarly, active
contraction cannot account for the beneficial effects on
cardiac structure and function observed after transplantation
of SMCs, which are incapable of repetitive rapid
contractions.
Although the functional characteristics of the cells them-
selves may be important, such as the ability to contract, it is
possible that some of the beneficial effects of cell transplan-
tation may be the result of attenuated ventricular dilatation
through a reorganization of the ECM surrounding the en-
grafted cells. In theory, because myocardial matrix disrup-
tion can decrease systolic performance without changing
myocyte contractility,19 engrafted cells could improve over-
all cardiac function without themselves contributing to con-
tractile function and may do so by restoring deficient inter-
stitial matrix components lost in the process of heart failure.
The use of cell engraftment to restore the content and spatial
organization of key ECM components in the failing heart is
conceivable, although this concept has never been formally
evaluated before this study. We hypothesized that muscle
cell transplantation may provide its benefits on structural
cardiac remodeling by limiting matrix degradation, perhaps
by regulating the MMP-TIMP axis, the central mechanism
that controls matrix remodeling in the failing heart.
To eliminate the possibility of host cell contraction re-
sulting in beneficial effects, we used VSMCs for cell trans-
plantation, which are incapable of rapid contraction com-
mensurate with the cardiac cycle. Prior studies have
determined that SMC transplantation results in consistent
and similar beneficial effects on preserving cardiac structure
and function compared with cardiac or skeletal muscle cell
sources.1-3,20 Compared with skeletal myoblasts and bone
marrow progenitor cells, VSMC transplantation has not
The Journal of ThoracicFigure 6. Confocal micrographs of fibrillar collagen network. Cell
transplantation using VSMCs prevented the characteristic loss of
collagen content in viable regions of LV myocardium and pre-
vented perimysial fiber thinning and fragmentation compared
with media-injected controls. All assessments were performed in
age-matched hamsters at 25 weeks of age in normal (A), dilated
cardiomyopathic (B), or cell-transplanted dilated cardiomyo-
pathic hamsters (C). Bar  50 m.and Cardiovascular Surgery ● Volume 130, Number 5 1435
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SMCs may offer some unique benefits over other cell types
for clinical cell transplantation such as ease of harvest, rapid
in vitro expansion, and a capacity for hyperplasia and hy-
pertrophy in response to hemodynamic stimuli. In addition,
VSMCs are capable of secreting angiogenic factors and
ECM components, characteristics that may enhance cell
engraftment and survival after implantation However, these
proposed advantages are currently speculative and remain to
be proven by further studies.
Allaire and colleagues21 recently tested the hypothesis
that the presence or absence of VSMCs modulates ECM
destruction by proteases and the spreading of inflammation
to the aortic media, which represent early events in the
formation of aneurysms. VSMCs were seeded onto decel-
lularized aortas and then implanted in the abdominal aorta
of rats. The presence of VSMCs in the arterial wall signif-
icantly enhanced the expression of TIMPs, specifically
TIMP-2 and TIMP-3, resulting in reduced inflammation. In
addition, the enhanced TIMP expression prevented proteo-
lytic ECM degradation and, in so doing, maintained vessel
wall integrity. It follows that VSMCs secrete TIMPs and
exert a profound paracrine effect that participates in vessel
wall homeostasis against inflammation and matrix proteol-
ysis. Other studies support this concept.22,23 For example,
Blindt and colleagues23 determined that VSMCs constitu-
tively express TIMP-2, TIMP-3, and collagen, and the ex-
pression of these matrix genes can increase in response to
environmental cues. Accordingly, VSMCs actively respond
to external stresses and environmental stimuli by secreting
bioactive molecules and ECM components. Under normal
physiologic conditions, VSMCs maintain local matrix ho-
meostasis by continually producing and secreting
TIMPs.23,24-26 The bioactive properties of the secreted
TIMPs limit MMP activity promoting structural matrix
stability.
We assessed the effects of VSMC engraftment in ham-
ster cardiomyopathy on differential TIMP expression and
parameters of matrix remodeling. Cell transplantation with
VSMCs enhanced the expression of TIMP-2 and TIMP-3.
These data are in keeping with a contractile VSMC pheno-
type, and, indeed, transplanted VSMCs were observed to
engraft in the myocardium and express contractile pheno-
typic markers. Remarkably, both matrix content and its
structural integrity were improved in the cell-transplanted
hearts, indicating a protective effect against matrix proteol-
ysis. Gelatinase MMP activity was attenuated in cell-trans-
planted hearts. We previously demonstrated that an imbal-
ance of TIMP-3 relative to MMP-9 directly results in a
dilated cardiomyopathy by accelerated matrix degrada-
tion.11 In addition, a restoration of the relative balance of
TIMP-3 with MMP-9 was associated with reverse remod-
eling in human patients after mechanical unloading of the
1436 The Journal of Thoracic and Cardiovascular Surgery ● Novfailing heart.27 Furthermore, the balance of TIMP-3 with
MMP-9 regulates ECM homeostasis and tissue remodeling
during development.28 In the present study, cell transplan-
tation increased the ratio of TIMP-3 to MMP-9 and the ratio
of TIMP-2 to MMP-2, indicating a reduced capacity for
matrix degradation and preserved myocardial matrix
homeostasis.
Important to our observation of the effects of cell trans-
plantation on matrix integrity are the extensive data indi-
cating that SMC transplantation provides significant bene-
fits on preserving LV function in experimental models of
cardiac disease, including hamster cardiomyopathy, with
effects similar to heart cell transplantation.2,3,16 We propose
the novel concept that SMC transplantation may exert its
protective effects on the progression of cardiomyopathy in a
paracrine manner by restoring the balance of TIMP expres-
sion relative to MMPs and thereby promoting matrix reor-
ganization in the failing heart. Cell transplantation appears
to alter matrix homeostasis toward a healthy functional
matrix, rather than excessive alteration of the remodeling
process resulting in maladaptive fibrosis. Further studies
will be required to determine whether this mechanism is
responsible for the benefits of other muscle cell types on the
remodeling process in the failing heart. In the context of
regional myocardial infarction, it is conceivable that cell
transplantation could restore damaged matrix elements re-
sulting in reduced scar expansion and attenuated structural
remodeling.29 We recognize that the process of cell engraft-
ment is complex, and that the biologic effects of cell trans-
plantation in the failing heart likely involve multiple cellular
and molecular pathways. However, on the basis of these
data, the TIMP-MMP axis may have an important contri-
bution to this intriguing process.
Limitations
First, we cannot conclusively establish a cause and effect
relationship between the enhanced expression of TIMPs
after cell transplantation and the simultaneous reduction in
matrix degradation and limitation of ventricular dilatation.
Thus, it is possible that the altered TIMPs are secondary to
the improved myocardial environment afforded by cell
transplantation. However, it is widely acknowledged that
the relative balance of MMPs with TIMPs drives the local
matrix environment, and in support, we observed improved
matrix content and organization after cell transplantation.
Second, we cannot establish the source of the enhanced
TIMP secretion from these data, although we presume that
the implanted cells were the primary donor. Because
TIMP-2 expression is not characteristically altered in ham-
ster cardiomyopathy,9 the enhanced expression of this
TIMP species suggests that its enhanced expression was a
product of the engrafted cells, which are known to readily
produce and secrete TIMP-2,23 particularly when trans-
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studies should establish the cellular source of the elevated
TIMP expression. We are actively pursuing these studies by
selectively transplanting TIMP-deficient cells into animal
models of cardiomyopathy to determine whether the bene-
fits of cell therapy are lost in the absence of TIMP expres-
sion. Third, dose-response studies were not used in the
current study, and these observations may provide addi-
tional mechanistic insights if performed.
Conclusion
The cellular and molecular mechanisms that govern cell
engraftment and the subsequent improvements of cardiac
function in the failing heart are likely multifactorial, com-
plex, and far from understood. From the perspective that
cardiac remodeling determines the clinical progression of
heart failure and is emerging as a therapeutic target in heart
failure of all causes,15 the mechanisms underlying cell
transplantation are an important area of investigation. These
data provide the first evidence that muscle cell transplanta-
tion limits ventricular dilatation in the failing heart by
preserving ECM homeostasis through a paracrine-mediated
mechanism. Gene-enhanced cell transplantation with spe-
cific TIMPs may optimize the ability of engrafted cells to
attenuate maladaptive remodeling and the progression to
heart failure.
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Dr Robert C. Robbins (Stanford, Calif). What is the underlying
mechanism of the dilatation in these hamsters? Is it an increased
degradation? Is that what causes their heart failure?
Dr Fedak. We previously published data in the American
Journal of Physiology that implicated the TIMP-MMP axis in the
process of hamster dilated cardiomyopathy. Our observations in
these hamsters implicated a progressive loss of TIMP expression
and excessive MMP-mediated matrix degradation as an important
mechanism underlying left ventricular dilatation and failure. These
findings were identical in our patients with end-stage dilated
cardiomyopathy, suggesting a similar mechanism in human dis-
ease.
Dr Robbins. What other cells have you tried in this particular
model, a nonischemic model of heart failure?
Dr Fedak. By using a model of hamster cardiomyopathy, we
previously performed cell transplantation with heart cells, skel-
etal muscle cells, SMCs, and bone marrow cells. All of these
cell types improved cardiac structure and function, and did so to
a similar extent. Given the consistent benefits of these diverse
cell types in both nonischemic and ischemic cardiomyopathy,
we entertained the idea that the process of cell engraftment
alone may provide beneficial effects on host myocardium,
somewhat independent of the cell type. Perhaps when a cell
engrafts in the host environment it alters its local environment
to maintain its survival. This process may involve the release of
paracrine factors that alter angiogenesis, cell growth, and cell
survival. Because cells engraft by incorporating into the local
interstitial matrix it is likely that the cells must alter this matrix
and act to maintain its integrity to survive. Perhaps the reorga-
nization of damaged ECM components during cell engraftment
is a simple explanation that can account for the profound
attenuation of ventricular dilatation observed with a diverse
group of cell types and models of heart failure.
Dr Robbins. What is the signal? Have you found any signal
that the cells are releasing that can cause the effects you have
observed in your cell signaling?
Dr Fedak. Our data suggest that cell transplantation enhances
the expression of specific TIMP proteins in the host myocardium.
We previously outlined that cardiac TIMP deficiency is sufficient
to induce maladaptive structural cardiac remodeling consistent
with a dilated cardiomyopathy. Cell transplantation may restore
deficient TIMP species and in so doing improve matrix homeosta-
sis. Improved matrix architecture enhances structural support and
prevents progressive LV dilatation and failure. In addition, the
ECM is far more than just a structural support system. It really is
the signaling interface for the cells. The matrix is where the growth
factors are pooled and the cell signals converge. Accordingly, if
you improve local matrix you probably also change signaling
systems in a profound way, and this may be, at least in part, how
the beneficial effects on structural remodeling may be produced by
cell transplantation.
Dr G. Alexander Patterson (St Louis, Mo). I believe that
there are some data in other cell transplant modeling systems in
the transplant arena. There is some work from Hebert’s group in
Montreal in which they demonstrated a similar paracrine mech-
anism that I think, if I recall the details, has to do with renal
allograft vasculopathy. Surely this isn’t a specific thing relevant
1438 The Journal of Thoracic and Cardiovascular Surgery ● Novto cardiac cell transplantation. Do you have some thoughts on
that?
Dr Fedak. Absolutely. One thing we know from matrix biol-
ogy is that a cell cannot survive if it is not attached to a healthy
local matrix. So without a doubt, no matter what type of cell or
what organ it is, if the donor cell does not have a healthy matrix to
adhere to, it simply won’t survive. So if you have successful cell
engraftment, by definition, you must have a somewhat healthy
matrix. I would propose that if donor cells are going to survive in
any host tissue, the donor cells would be best served to actively
improve their local environment, particularly by helping to coor-
dinate and maintain matrix homeostasis. Because the matrix is
damaged in most disease states, including heart failure of all
causes, engrafted cells would likely provide benefits by improving
matrix structure and function. Improved matrix homeostasis would
have profound effects on overall tissue architecture and function,
which is what we see consistently with experimental and perhaps
even clinical cell transplantation.
Dr David H. Harpole, Jr (Durham, NC). This is a very elegant
study. What I really want to do is take 2 steps back. There has been
a tremendous amount of work in the TIMPs and so forth with
respect to controlling invasion and tumors. Have you all looked at,
first of all, any of the compounds, just directly injecting or putting
those in now that you define a mechanism?
And second, there are other ways that invasion takes place that
have to do with turning on and off this pathway. Do you think
those have a role in this as well?
Dr Fedak. You bring up 2 important issues. One is a question
of what we really need to be using as the therapy. Do we really
need the cells themselves or would injection of some sort of matrix
be of benefit? I think that is an interesting and testable idea with
direct clinical implications. If we find that we can restore damaged
matrix elements just by injecting an off-the-shelf matrix alone,
imagine the clinical possibilities? That is one important question.
Certainly we can target TIMP deficiency by TIMP gene-enhanced
cell transplantation. Our preliminary data using these enhanced
cells are very encouraging. By targeting the paracrine mediators
that mediate the benefits of cell transplantation with gene-enhance-
ment of the donor cells, we may best optimize use of this novel
therapy.
The second issue is that the TIMPs themselves not only
inhibit the MMPs but also have many other important biologic
effects. As you mention, the role of TIMPs in cancer invasion
is a prime example. TIMPs have been implicated to have direct
effects on cell death, growth, migration, and signaling through
growth factor activation. Probably what I am presenting here is
a simplistic version of what is in reality a very complex phe-
nomenon.
Dr Masashi Komeda (Kyoto, Japan). I enjoyed your talk very
much. It is very interesting. We did a study using hepatocyte
growth factor slow-release method to dilated cardiomyopathy, 2 of
them. One is a spontaneous hypertension rat model, and the other
is an antimyosin cardiomyopathy model. In either case, by de-
creasing too much fibrosis, cardiac function recovered well, and
we showed that amount of fibrosis decreased.
From your model, I got the impression that there are good and
bad aspects of matrix, and maybe it is in part model-dependent, but
maybe we have to get more information about which elements
ember 2005
Fedak et al Cardiothoracic Transplantationshould be decreased and which should be preserved. I want to hear
your opinion about that.
Dr Fedak. Thank you for your question, Dr Komeda. I am
familiar with your work. Indeed, matrix remodeling is a com-
plex phenomenon. It is confusing, because increased matrix
degradation is often observed in association with increased total
amounts of collagen. Matrix alterations are dependent on the
mode of injury as well as the timing and location of the analysis
being performed. These parameters may show significant dif-
ferences depending on the stage of the disease. In this study we
looked specifically at perimysial collagen fibers, which we
believe are the key for structural support. Perimysial collagen
content and architecture are disrupted in dilated cardiomyopa-
thy. That is not to say that there isn’t increased total collagen in
these hearts. Scarring and fibrosis occur, as you mentioned, but
that seems to be more of an inflammatory process around blood
vessels and areas of focal cell necrosis, as opposed to the
The Journal of Thoracichealthy and active matrix that we targeted in our analysis using
confocal microscopy.
Dr Komeda. There are 2 different aspects of the cardiomyop-
athy. They are similar in part, but in part different. There is
restricted or dilated, purely dilated, or a combination. In your
model maybe it is a purely dilated model and not too much
diastolic dysfunction.
Dr Fedak. That is correct, it is a model of progressive
dilated cardiomyopathy. I agree that our model is primarily that
of LV dilatation, compared with other models that have tran-
sient compensated hypertrophy phases. However, LV dilatation
is the most important predictor of decompensation and death
from heart failure. I would argue that in the context of conges-
tive heart failure, the LV dilatation we see in our patients is
really the disease itself. I believe that we should target LV
dilatation in terms of developing novel surgical approaches,
such as cell transplantation and others.
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